Review article: A variable level of prostate specific antigen and its relative tests and their probable explanatory diagnosis
Article Sidebar
Main Article Content
Abstract
prostate specific antigen is a glycoprotein that liquefy the semen normally. It suppose to be in a very low level abnormally and increase in cases of infection of the prostrate, hyperplasia and tumor. Due to increase and decrease in many other cases not only a tumor and due to high percent of existence in many normal fluids and many other tumor, it somewhat reduce its specifity and sensitivity and so it supported by other test. Aim: it to predict whether that tumor marker is sufficient to the diagnosis of the prostate tumor. Nowadays it had been seen that this tumor marker is secreted from many other fluid beside the prostate gland and found in many other tumor beside the prostate tumor and so it is better to be supported by many other assessments and clinical and histological steps for making a definite decision.
Article Details
References
Balk SP, Ko YJ, Bubley GJ (January 2003). "Biology of prostate specific antigen". Journal of Clinical Oncology. 21 (2): 383–91.
Freedland SJ, Sutter ME, Dorey F, Aronson WJ (February 2003). "Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate specific antigen". Urology. 61 (2): 365–9
Velonas VM, Woo HH, dos Remedios CG, Assinder SJ (2013). "Current status of biomarkers for prostate cancer". International Journal of Molecular Sciences. 14 (6): 11034–60.
Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG (2002). "Free prostate specific antigen in serum is becoming more complex". Urology. 59 (6): 797–802.
Naya Y, Okihara K (2004). "Role of complexed PSA in the early detection of prostate cancer". Journal of the National Comprehensive Cancer Network. 2 (3): 209–12.
Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, et al. (October 2011). "Screening for prostate cancer: the current evidence and guidelines controversy". The Canadian Journal of Urology. 18 (5): 5875–83.
Grossman DC, Curry SJ, Owens DK, Bibbins Domingo K, Caughey AB, et al. (2018). "Screening for Prostate Cancer". JAMA. 319 (18): 1901–1913
Leong AS, Cooper K, Leong FJ (2003). Manual of Diagnostic Cytology (2nd ed.). Greenwich Medical Media, Ltd. pp. 79–80
"Should I have a PSA test?" Archived 2018 02 28 at the Wayback Machine, NHS Choices, 27 February 2018
Grossman DC, Curry SJ, Owens DK, Bibbins Domingo K, Caughey AB, et al. (2018). "Screening for Prostate Cancer". JAMA. 319 (18): 1901–1913. doi:10.1001/jama.2018.3710. ISSN 0098 7484. PMID 29801017.
Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J (8 May 2018). "Prostate Specific Antigen–Based Screening for Prostate Cancer". JAMA. 319 (18): 1914–1931.
Freedland SJ, Sutter ME, Dorey F, Aronson WJ (February 2003). "Defining the ideal cut point for determining PSA recurrence after radical prostatectomy. Prostate specific antigen". Urology. 61 (2): 365–9.
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. (May 2004). "Prevalence of prostate cancer among men with a prostate specific antigen level < or =4.0 ng per milliliter". The New England Journal of Medicine. 350 (22): 2239–46.
Cao Y, Ma J (April 2011). "Body mass index, prostate cancer specific mortality, and biochemical recurrence: a systematic review and meta analysis". Cancer Prevention Research. 4 (4): 486–501
Herschman JD, Smith DS, Catalona WJ (August 1997). "Effect of ejaculation on serum total and free prostate specific antigen concentrations". Urology. 50 (2): 239–43.
Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL (August 1995). "Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels". The Journal of Urology. 154 (2 Pt 1): 407–13.
Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, et al. (1992). "The effect of digital rectal examination on prostate specific antigen levels". JAMA. 267 (16): 2227–8
Connolly D, Black A, Murray L, Gavin A, Keane P (2007). "798 Population Based Age Specific Reference Ranges for PSA". European Urology Supplements. 6 (2): 222
Catalona WJ, Smith DS, Ornstein DK (May 1997). "Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements". JAMA. 277 (18): 1452–5.
Stura EA, Muller BH, Bossus M, Michel S, Jolivet Reynaud C, Ducancel F (December 2011). "Crystal structure of human prostate specific antigen in a sandwich antibody complex". Journal of Molecular Biology. 414 (4): 530–44.
Mattsson JM, Valmu L, Laakkonen P, Stenman UH, Koistinen H (June 2008). "Structural characterization and anti angiogenic properties of prostate specific antigen isoforms in seminal fluid". The Prostate. 68 (9): 945–54
Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI (August 2007). "Immunohistochemical differentiation of high grade prostate carcinoma from urothelial carcinoma". The American Journal of Surgical Pathology. 31 (8): 1246–55